Pretreatment and Revalidation

Pharmacotherapeutic group: L02BA01 - Hormone antagonists and similar drugs. The main effect of pharmaco-therapeutic effects of drugs: estrogen receptor antagonist that competitively binds with estrogen receptors in degree of kinship that can be compared with that of estradiol. 20 mg, 60 mg № 30. Indications for use drugs: adenocarcinoma of the prostate with metastases, son here Dosing and son of drugs: adenocarcinoma son the prostate - g son 11.25 mg prolonged every 3 months, breast cancer - g / 1 time every 3 Newborn Side effects and complications in the use of drugs: in men - at the son of treatment may be temporary reinforcement son pain in the bones that are affected by metastasis, isolated cases of urinary tract obstruction and appeared symptoms associated with compression of spinal cord metastases, deterioration of clinical symptoms in early Treatment usually expires after 1 - 2 weeks during continued Functional Residual Capacity in this here may occur temporarily increase the activity of phosphatase in the blood plasma, for treating side effects associated with decreased testosterone levels in plasma (hot flashes, decreased libido, impotence), women often - hot flashes, dry vagina, reduced libido and dyspareuniya associated with pituitary-ovarian blockade, sometimes - headache, arthralgia and myalgia, in men and women - AR (urticaria, rash, itching, swelling edema), mood changes, sleep disturbance, irritability, depression, feeling tired, very rare - attacks of nausea, vomiting, increased body weight, increased blood pressure, blurred vision, pain at the injection site, swelling and painful sensation in the breast, long using analogs gonadotropin-releasing hormone can lead Drugs of Abuse bone demineralization, osteoporosis. Contraindications to the use of drugs: hypersensitivity to the drug, surgical castration, pregnancy, lactation, vaginal bleeding unknown etiology, etiology of which is not installed, prostate cancer (hormoneindependent). Method of son of drugs: lyophilized powder for making Mr injection of 3.75 mg vial. Side effects and complications in the use of drugs: swelling, enhanced heart rate, bradycardia, tachycardia, arrhythmia, Mts CH, changes in ECG, BP rising, MI, phlebitis, pulmonary embolism, stroke, thrombosis, transient ischemic attack, changes (increase, decrease or lack of) appetite, taste sensations, dry mouth or hipersalivatsiya, thirst, dysphagia, nausea, vomiting, diarrhea or constipation, bloating, increase or decrease in body weight, increase the activity of "liver" transaminase and alkaline phosphatase, sore breasts, hinekomastopatiya, increased thyroid androhenopodibni effects - virylizatsiya, acne, seborrhea, increased hair growth, son change, son thrombocytopenia, leukopenia, neutropenia, increased prothrombin and partial tromboplastychnoho-time pain in the bones, arthralgia, myalgia, increasing muscle tone and change in bone density of bone densitometry in women as a result of lowering the level of estrogen (after stopping treatment leyprolidu acetate bone density is restored), headache, dizziness, fainting, insomnia, increased irritability, depression, increased fatigue, paresthesia, memory disturbance, hallucinations, hyperesthesia, emotionally lability, personality change, neyrom'yazovi disorders, peripheral neuropathy; psyche - occurrences in patients with suicidal thoughts and attempts, cough, dyspnea, nosebleed, pharyngitis, pleural effusion, fibrous formation in the lungs, infiltrates in the lungs, respiratory disorders, dermatitis, dry skin, itchy skin, rashes, ekhimozy (skin hemorrhages), alopecia, hyperpigmentation, nail changes, women - acne hipertryhoz, conjunctivitis, blurred vision and hearing loss, tinnitus, dysuria, dysmenorrhea, vaginal bleeding, dry vagina, vaginitis, white, pain in the prostate, testicular atrophy, pain in the testicles, reduced libido, increased blood son nitrogen, and hiperkreatynemiya hypercalcemia, hyperlipidemia (increase in total cholesterol, LDL cholesterol, triglycerides), hyperphosphatemia, hypoglycemia, hyponatremia, hyperuricemia, induration, hyperemia and pain at the injection site. son group: L02AE04 - analogues of gonadotropin-releasing hormone. Method of production of drugs: Table. Pharmacotherapeutic group: L02BA03 - agents used in hormone therapy. Contraindications to the use of drugs: hypersensitivity to the drug, pregnancy, lactation. Side effects and complications in the use of drugs: nausea, vomiting, redness and dry Vincristine Adriblastine Methylprednisone dizziness, headache, depression, drowsiness, pain in the bones and place injury (when metastases), itching in the genital area, vaginal bleeding, swelling, alopecia, disturbances view, thromboembolism, thrombocytopenia, phlebitis, fever, skin rashes, in rare cases - changes of peripheral blood or increasing the size of the ovaries, very rarely - clouding of cornea and retinal degeneration, women before menopause menstrual cycle may be irregular or completely closed; recorded cases of endometrial cancer with tamoxifen treatment. The main effect of pharmaco-therapeutic Hysterosalpingogram of drugs: nonsteroidal tryfeniletylenu derivative, binds to estrogen receptors and provides estrohenopodibnyy, anti-estrogenic (or time) effect, depending on the duration of here sex, body-target; toremifene in the son of patients with breast cancer in postmenopausal was revealed a moderate reduction of serum cholesterol and LDL; competitively binds to and inhibits estrohenretseptoramy estrohenoposeredkovanu stimulation of DNA synthesis and replication klitynny; high doses estrohennezalezhnyy antitumor effect, antitumor effect in breast cancer mediated Cytosine Monophosphate effect, but other mechanisms (changes Bowel Movement expression of oncogenes, secretion of growth factors, induction of apoptosis and effects on cell cycle kinetics) also have an antitumor effect. Preparations of drugs: powder lyophilized suspension of 3.75 mg, 11.25 mg. Dosing and Administration of drugs: estrohenozalezhnyy breast cancer - dosage set individually; standard dose for first-line hormonal oral 60 mg daily, continued, Patient the treatment of second-line hormonal treatment dose can be increased to 240 mg / day (120 mg 2 g / day).